# Bing Yuan

> Bing Yuan is the co-founder and CEO of OnCusp Therapeutics. Trained at Nanjing University, Columbia University and Cornell University, he held business-development and strategy roles at Eisai, Novartis, Merck and CStone before co-founding OnCusp in 2021 with Eric Slosberg and Andy Fu. His documented career centers on international partnerships, organizational development and financing.

- **Role:** Co-Founder and Chief Executive Officer at OnCusp Therapeutics
- **Organizations:** OnCusp Therapeutics, CStone Pharmaceuticals, Merck (MSD), Novartis, Eisai, Thermo-Fisher, BioKatalyst
- **Education:** Bachelor of Science in Biochemistry, Nanjing University, Master of Arts in Cellular, Molecular and Biomedical Studies, Columbia University, Master of Philosophy in Cellular, Molecular and Biomedical Studies, Columbia University, PhD in Cellular, Molecular and Biomedical Studies, Columbia University, MBA, Cornell University
- **Known for:** Helped build CStone from an early startup through its 2019 listing., Established and managed more than ten business functions at CStone, according to published biographies., Worked on CStone partnerships with Pfizer, Bayer, Blueprint, Agios and EQRx.

## Career timeline

- **—** — Product Manager at Thermo-Fisher; subsequently held a global marketing role at Eisai.
- **2008-2014** — Held global commercial roles at Novartis, including Executive Director and Head of Life Cycle Strategy; tenure January 2008 to July 2014.
- **Before 2016-11** — After Novartis and before CStone, served as Executive Director and global business-development lead at Merck (MSD); exact start date unverified.
- **2016** — Joined CStone Pharmaceuticals in November.
- **2019** — Served on CStone’s executive team when the company listed in Hong Kong on February 26.
- **2020** — Served as CStone’s Chief Strategy and Business Officer.
- **2021** — Left CStone in February and co-founded OnCusp with Eric Slosberg and Andy Fu; company established in April with $25 million seed financing.
- **2022** — Participated in World Innovators Meet in New York on July 30; featured on Behind Biotech on June 2.
- **2024** — OnCusp announced a $100 million Series A and $139 million cumulative financing on January 4.
- **2026** — As CEO, welcomed Anthony Kim’s appointment as CFO on May 14.

## Achievements

- Helped build CStone from an early startup through its 2019 listing.
- Established and managed more than ten business functions at CStone, according to published biographies.
- Worked on CStone partnerships with Pfizer, Bayer, Blueprint, Agios and EQRx.
- Co-founded OnCusp in 2021 and built an international team; the company reported $139 million cumulative financing in January 2024.
- Three-time recipient of the Novartis Oncology President Award, according to his 2016 speaker biography.

## Latest updates

- **2026-05** — OnCusp appointed Anthony Kim as CFO; Yuan emphasized his investor-relations and financing experience.
- **2024-01** — OnCusp announced a $100 million Series A co-led by Novo Holdings, OrbiMed and F-Prime Capital, bringing reported cumulative financing to $139 million.

## Links

- Website: https://www.oncusptx.com/
- LinkedIn: https://www.linkedin.com/in/bing-yuan-7653142/

---

Profile page: https://yespress.io/bing-yuan
Published by YesPress — https://yespress.io
Last updated: 2026-10-26